Compare NYAX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | MESO |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | Israel | Australia |
| Employees | N/A | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2022 | N/A |
| Metric | NYAX | MESO |
|---|---|---|
| Price | $71.77 | $15.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $49.50 | N/A |
| AVG Volume (30 Days) | 24.4K | ★ 188.2K |
| Earning Date | 05-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | $629.74 |
| Revenue Next Year | $21.70 | $30.65 |
| P/E Ratio | $89.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.50 | $9.88 |
| 52 Week High | $70.50 | $21.50 |
| Indicator | NYAX | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 74.59 | 53.18 |
| Support Level | $42.74 | $15.62 |
| Resistance Level | N/A | $16.37 |
| Average True Range (ATR) | 1.55 | 0.37 |
| MACD | 0.73 | 0.02 |
| Stochastic Oscillator | 98.01 | 53.52 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.